Kleo Pharmaceuticals, the five-year-old New Haven biotech based in Science Park, has secured a $5 million grant from the Bill & Melinda Gates Foundation for its drug to combat COVID-19.
Kleo said it will use the funding to advance a treatment that will leverage the company’s MATE (Monoclonal Antibody Therapy Enhancer) technology to fight SARS-CoV-2, the virus that causes COVID-19.